Veradigm Announces Collaboration With Lash Group to Streamline Patient Care
May 25 2021 - 8:01AM
Business Wire
Allscripts and AmerisourceBergen businesses are
accelerating the fulfillment of specialty medications through
innovation and automation in support of physician practices,
patient adherence and better outcomes
Veradigm®, a leading provider of data and technology solutions
and a business unit of Allscripts Healthcare Solutions (NASDAQ:
MDRX), today announced an agreement with Lash Group, a patient
support services business, and a part of AmerisourceBergen. This
relationship will enable specialty medications, supported by Lash
Group, to be available for management within the Veradigm AccelRx™
platform, which streamlines the specialty enrollment process for
users of Veradigm, Allscripts’ and other electronic health record
(EHR) software vendors.
To obtain their specialty medication, a patient’s prescription
passes through a range of healthcare stakeholders, including
payers, patient support programs and pharmacies. All have long
sought tech enablement, further upstream in the EHR and providers’
native workflow, to simplify and automate the analog work that
drive gaps in clinical data, phone calls and faxes to the clinic
and extended wait times for patients to receive their prescribed
medications. Through this collaboration, Veradigm and Lash Group
can deliver a frictionless solution that will drive efficiency,
resulting in a streamlined process and increased
speed-to-therapy.
Combining one of healthcare’s largest prescriber bases, an
innovative cloud-based software solution, and decades of
e-prescribing and prior authorization leadership, Veradigm AccelRx™
delivers a unique breakthrough solution that is helping to
streamline specialty medication management for medical clinics and
practices across the country.
“It is critical that new technologies are employed to get
patients on their therapies more quickly to improve health
outcomes. This strategic relationship with Lash Group is a major
step in Veradigm’s progress toward expediting the specialty drug
review, approval and fulfillment process,” says Tom Langan,
Veradigm CEO. “In collaborating with a market leader with extensive
reach like Lash Group, we enable our broad network of providers to
access even more specialty medications through Veradigm AccelRx™.
Together, we will make a meaningful difference for patients and the
providers that serve them.”
“As the specialty pharmaceutical market has grown, we’ve
continued to evolve our support to remove barriers, simplify the
patient experience and accelerate patient access to the treatment
they need,” said Lash Group President Tommy Bramley. “This
collaboration with Veradigm is the latest example of how we are
working with organizations across the industry to create robust,
integrated offerings that further enhances our ability to support
patients and improve their quality of life.”
Learn more about the Veradigm AccelRx™ solution here.
About Veradigm®
Veradigm is an integrated data systems and services company that
combines data-driven clinical insights with actionable tools to
help healthcare stakeholders improve the quality, efficiency, and
value of healthcare delivery— including biopharma, health plans,
healthcare providers, health technology partners, and most
importantly, the patients they serve. We are dedicated to
simplifying the complicated healthcare system with next-generation
healthcare solutions. This is how we are transforming health,
insightfully. To learn more, visit www.veradigm.com. Veradigm® is a
business unit of Allscripts.
About Allscripts
Allscripts (NASDAQ: MDRX) is a leader in healthcare information
technology solutions that advance clinical, financial and
operational results. Our innovative solutions connect people,
places and data across an Open, Connected Community of Health™.
Connectivity empowers caregivers to make better decisions and
deliver better care for healthier populations. To learn more, visit
www.allscripts.com, Twitter, YouTube and It
Takes A Community: The Allscripts Blog.
© 2021 Allscripts Healthcare, LLC and/or its affiliates. All
Rights Reserved.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210525005348/en/
Investors: Stephen Shulstein
312-386-6735 Stephen.Shulstein@allscripts.com
Media: Concetta Rasiarmos
312-447-2466 concetta.rasiarmos@allscripts.com
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Apr 2023 to Apr 2024